US-based Mystic Pharmaceuticals has secured two Notices of Allowance from the US Patent Office for its Unit Dose Drug Delivery Platform and Piercing Device for Drug Delivery Systems patent applications.
According to the company, the new patents will expand its novel VersiDoser and VRx2 delivery platforms used to develop patient-centric pharmaceutical products.
Additionally, the company is using its new delivery technology for the development of therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.
Mystic president and CEO Timothy Sullivan said in order to provide better health outcomes the pharmaceutical industry has shifted from product-oriented to patient-oriented products.
"Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products," Sullivan added.
"These latest innovations further expand our capabilities to enhance the patient experience by making pharmaceutical products that are safer, easier and more convenient to use."
The change to patient-centric product development strategies will help the consumer by providing improved compliance and health outcomes.
Pharmaceutical and biotech firms can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics by using the company's delivery platform technologies.
